PDCD1 and neoplasm: Abbas et al. designed a new peptide targeting PD-1, FITC-YT-16, which significantly enhanced the anti-tumor activity of T cells in vitro404, while Sasikumar et al. designed the peptide NP-12 to bind PD-L1 competitively with PD-1.